← All Vistagen Therapeutics, INC filings

Vistagen Therapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
VTGN
Vistagen Therapeutics, INC
DEF: Vistagen Therapeutics Sets 2026 Annual Meeting Date
Vistagen Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for September 10, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.
NASDAQ
VTGN
Vistagen Therapeutics, INC
DEFA14A: Vistagen Therapeutics Files Definitive Proxy Materials
Vistagen Therapeutics, Inc. has filed definitive additional proxy soliciting materials with the SEC.
NASDAQ
VTGN
Vistagen Therapeutics, INC
DEF: Vistagen Therapeutics Advances Key Clinical Trials, Prepares for 2025 Annual Meeting Amid Leadership Changes
Vistagen Therapeutics, Inc. reports significant progress in its fasedienol Phase 3 clinical program for social anxiety disorder, with topline results expected in late 2025 and early 2026, while announcing its upcoming virtual Annual Meeting and a director's retirement.
NASDAQ
VTGN
Vistagen Therapeutics, INC
DEFA14A: Vistagen Therapeutics Files Definitive Proxy Statement
Vistagen Therapeutics has filed a definitive proxy statement with the SEC.
NASDAQ
VTGN
Vistagen Therapeutics, INC
DEF 14A: Vistagen Therapeutics Sets Date for 2024 Annual Stockholders Meeting Amidst Clinical Development Progress
Vistagen Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on August 26, 2024, highlighting progress in clinical trials and pipeline development.
NASDAQ
VTGN
Vistagen Therapeutics, INC
DEF 14A: Vistagen Therapeutics Seeks Stockholder Approval for Equity Incentive Plan and Employee Stock Purchase Plan Amendments
Vistagen Therapeutics is holding a special meeting to seek stockholder approval for amendments to its equity incentive plan and employee stock purchase plan to increase the number of shares available for issuance.